COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,436 Articles (22,835 medRxiv, 8,601 bioRxiv)

Most recent first Previous |  Page 670: Articles 6691-6700  | Next

UB-612 Multitope Vaccine Targeting SARS-CoV-2 Spike and Non-Spike Proteins Provides Broad and Durable Immune Responses
Wang, C. Y., Peng, W.-J., Kuo, B.-S., Liu, H., Ho, Y.-H., Wang, M.-S., Yang, Y.-T., Chang, P.-Y., Shen, Y.-H., Hwang, K.-P.
10.1101/2022.08.26.22279232 — Posted: 2022-08-30
Effectiveness of endurance training rehabilitation after hospitalisation in intensive care for COVID-19-related acute respiratory distress syndrome on dyspnoea (RECOVER): a randomised controlled, open-label multicentre trial
Romanet, C., Wormser, J., Fels, A., Lucas, P., Prudat, C., Sacco, E., Bruel, C., Pantefeve, G., Pene, F., Chatellier, G., Philippart, F.
10.1101/2022.08.29.22279327 — Posted: 2022-08-30
An effective volunteer community-based COVID-19 response program: the Vashon, WA Medical Reserve Corp experience
Bristow, J., Olney, C. J., Vashon MRC COVID-19 Steering Committee, , Weinshel, J., Rovig, R., Wallace, R., Lindquist, K. J.
10.1101/2022.08.26.22279283 — Posted: 2022-08-30
Coverage and correlates of COVID-19 vaccination among children aged 5-11 years in Alberta, Canada
MacDonald, S. E., Reifferscheid, L., Paudel, Y. R., ROBINSON, J.
10.1101/2022.08.29.22279354 — Posted: 2022-08-30
A Phase I, Prospective, Randomized, Open-labeled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901(Beta) SARS-CoV-2 Vaccine in Adults
Lien, C. E., Liu, M.-C., Wang, N.-C., Liu, L. T. -C., Wu, C.-C., Tang, W.-H., Lian, W.-C., Huang, K.-Y. A., Chen, C.
10.1101/2022.08.29.22279317 — Posted: 2022-08-30
Metformin is Associated with Reduced COVID-19 Severity in Patients with Prediabetes
Chan, L. E., Casiraghi, E., Laraway, B. J., Coleman, B., Blau, H., Zaman, A., Harris, N. L., Wilkins, K., Valentini, G., Sahner, D., Haendel, M. A., Robinson, P. N., Bramante, C. T., Reese, J. T.
10.1101/2022.08.29.22279355 — Posted: 2022-08-30
Impact of HLA divergence on humoral response to SARS-CoV-2 and HBV vaccines in the liver transplantation setting
Feray, C., Allain, V., Allain, J.-L., roche, B., Desterke, C., Kounis, I., Demir, z., Roque-Afonso, A.-M., Coilly, A., Samuel, D., Caillat-Zucman, S.
10.1101/2022.08.29.22279247 — Posted: 2022-08-30
Leveraging Natural Language Processing and Geospatial Time Series Model to Analyze COVID-19 Vaccination Sentiment Dynamics from Tweets
Ye, J., Hai, J., Wang, Z., Wei, C., Song, A. J.
10.1101/2022.08.26.22279278 — Posted: 2022-08-30
A Joint Compartmental Model for The Co-infection of SARS-CoV-2 and Influenza
Zafarnejad, R., Griffin, P. M., Ventresca, M.
10.1101/2022.08.26.22279281 — Posted: 2022-08-30
Comparison of influenza and COVID-19 hospitalizations in British Columbia, Canada: a population-based study
Setayeshgar, S., Wilton, J., Sbihi, H., Zandy, M., Janjua, N., Choi, A., Smolina, K.
10.1101/2022.08.26.22279284 — Posted: 2022-08-30

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).